期刊
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
卷 120, 期 5, 页码 1269-1273出版社
ELSEVIER TAIWAN
DOI: 10.1016/j.jfma.2020.08.022
关键词
SARS-CoV-2; Interleukin; Coronavirus; Interferon; Cytokine
资金
- National Taiwan University Hospital TOP DOWN Project [109-P13, 109P14]
In this case report, six patients with mild to moderate COVID-19 were treated with hydroxychloroquine for 14 days, showing no complications. However, prolonged virus shedding was still observed despite treatment with HCQ, and the impact on cytokine kinetics remained unclear.
Until now, there are no approved treatment against COVID-19. Hydroxychloroquine (HCQ) was hypothesized to be active against SARS-CoV2 via antiviral and anti-inflammatory effect; however, HCQ for COVID-19 in clinical use remained debating. In this preliminary report, we pre-sented six patients with mild to moderate COVID-19. They were treated with HCQ for 14 days from the day of COVID-19 diagnosis. Serial viral load from respiratory specimens were performed every other day. Cytokine profile was checked before HCQ initiation and on the 14th day of HCQ treatment. All patients receiving HCQ completed 14-day course without complication. Among the six patients, the mean duration from symptom onset to last detectable viral load was 34 + 12 days, which was similar to those without specific treatment in previous re-ports. Low level of interferon-gamma was noted in all patients of different stage of infection and three patients had elevation of IL-17 level. Prolonged virus shedding is still observed regardless HCQ. The impact of HCQ on cytokine kinetics remained unclear; however, IL-17 could be an inflammatory marker for disease status monitor and a potential therapeutic target. Copyright (c) 2020, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据